Yukihiko Hiroshima1, Ali Maawy2, Sho Sato3, Takashi Murakami3, Fuminari Uehara4, Shinji Miwa4, Shuya Yano4, Masashi Momiyama3, Takashi Chishima3, Kuniya Tanaka3, Michael Bouvet5, Itaru Endo3, Robert M Hoffman4. 1. AntiCancer, Inc, San Diego, California; Department of Surgery, University of California San Diego, San Diego, California; Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan. 2. Department of Surgery, University of California San Diego, San Diego, California. 3. Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan. 4. AntiCancer, Inc, San Diego, California; Department of Surgery, University of California San Diego, San Diego, California. 5. Department of Surgery, University of California San Diego, San Diego, California. Electronic address: mbouvet@ucsd.edu.
Abstract
BACKGROUND: In this study, we investigated the advantages of fluorescence-guided surgery (FGS) in mice of a portable hand-sized imaging system compared with a large fluorescence imaging system or a long-working-distance fluorescence microscope. METHODS: Mouse models of human pancreatic cancer for FGS included the following: (1) MiaPaCa-2-expressing green fluorescent protein, (2) BxPC3 labeled with Alexa Fluor 488-conjucated anti-carcinoembryonic antigen (CEA) antibody, and (3) patient-derived orthotopic xenograft (PDOX) labeled with Alexa Fluor 488-conjugated anti-carbohydrate antigen 19-9 antibody. RESULTS: Each device could clearly detect the primary MiaPaCa-2-green fluorescent protein tumor and any residual tumor after FGS. In the BxPC3 model labeled with Alexa Fluor 488-conjugated anti-CEA, each device could detect the primary tumor, but the MVX10 could not clearly detect the residual tumor remaining after FGS whereas the other devices could. In the PDOX model labeled with Alexa Fluor 488-conjugated anti-carbohydrate antigen 19-9, only the portable hand-held device could distinguish the residual tumor from the background, and complete resection of the residual tumor was achieved under fluorescence navigation. CONCLUSIONS: The results described in the present report suggest that the hand-held mobile imaging system can be applied to the clinic for FGS because of its convenient size and high sensitivity which should help make FGS widely used.
BACKGROUND: In this study, we investigated the advantages of fluorescence-guided surgery (FGS) in mice of a portable hand-sized imaging system compared with a large fluorescence imaging system or a long-working-distance fluorescence microscope. METHODS:Mouse models of humanpancreatic cancer for FGS included the following: (1) MiaPaCa-2-expressing green fluorescent protein, (2) BxPC3 labeled with Alexa Fluor 488-conjucated anti-carcinoembryonic antigen (CEA) antibody, and (3) patient-derived orthotopic xenograft (PDOX) labeled with Alexa Fluor 488-conjugated anti-carbohydrate antigen 19-9 antibody. RESULTS: Each device could clearly detect the primary MiaPaCa-2-green fluorescent protein tumor and any residual tumor after FGS. In the BxPC3 model labeled with Alexa Fluor 488-conjugated anti-CEA, each device could detect the primary tumor, but the MVX10 could not clearly detect the residual tumor remaining after FGS whereas the other devices could. In the PDOX model labeled with Alexa Fluor 488-conjugated anti-carbohydrate antigen 19-9, only the portable hand-held device could distinguish the residual tumor from the background, and complete resection of the residual tumor was achieved under fluorescence navigation. CONCLUSIONS: The results described in the present report suggest that the hand-held mobile imaging system can be applied to the clinic for FGS because of its convenient size and high sensitivity which should help make FGS widely used.
Authors: Michael P Kim; Douglas B Evans; Huamin Wang; James L Abbruzzese; Jason B Fleming; Gary E Gallick Journal: Nat Protoc Date: 2009-10-29 Impact factor: 13.491
Authors: Sharmeela Kaushal; Michele K McElroy; George A Luiken; Mark A Talamini; A R Moossa; Robert M Hoffman; Michael Bouvet Journal: J Gastrointest Surg Date: 2008-07-30 Impact factor: 3.452
Authors: Susan L Troyan; Vida Kianzad; Summer L Gibbs-Strauss; Sylvain Gioux; Aya Matsui; Rafiou Oketokoun; Long Ngo; Ali Khamene; Fred Azar; John V Frangioni Journal: Ann Surg Oncol Date: 2009-07-07 Impact factor: 5.344
Authors: Michele McElroy; Sharmeela Kaushal; George A Luiken; Mark A Talamini; A R Moossa; Robert M Hoffman; Michael Bouvet Journal: World J Surg Date: 2008-06 Impact factor: 3.352
Authors: Cristina A Metildi; Sharmeela Kaushal; George A Luiken; Robert M Hoffman; Michael Bouvet Journal: J Am Coll Surg Date: 2014-03-02 Impact factor: 6.113
Authors: Ali A Maawy; Yukihiko Hiroshima; Yong Zhang; Miguel Garcia-Guzman; George A Luiken; Hisataka Kobayashi; Robert M Hoffman; Michael Bouvet Journal: J Surg Res Date: 2015-02-19 Impact factor: 2.192
Authors: Yukihiko Hiroshima; Thinzar M Lwin; Takashi Murakami; Ali A Mawy; Tanaka Kuniya; Takashi Chishima; Itaru Endo; Bryan M Clary; Robert M Hoffman; Michael Bouvet Journal: J Surg Oncol Date: 2016-10-03 Impact factor: 3.454
Authors: Cristina A Metildi; Sharmeela Kaushal; Minya Pu; Karen A Messer; George A Luiken; Abdool R Moossa; Robert M Hoffman; Michael Bouvet Journal: Ann Surg Oncol Date: 2014-02-06 Impact factor: 5.344
Authors: Ali A Maawy; Yukihiko Hiroshima; Yong Zhang; George A Luiken; Robert M Hoffman; Michael Bouvet Journal: J Biomed Opt Date: 2014 Impact factor: 3.170